<DOC>
	<DOCNO>NCT02769689</DOCNO>
	<brief_summary>Progressive multifocal leukoencephalopathy ( PML ) fear complication natalizumab ( NTZ ) use treatment relapse multiple sclerosis ( MS ) . The risk PML increase 18 month treatment . When switch NTZ another disease modify treatment ( DMT ) MS patient active disease , high risk inflammatory reactivation . Nonetheless , washout period several week necessary initiate new DMT . The primary purpose protocol investigate impact high dose oral methylprednisolone , give month washout period NTZ Fingolimod ( FTY ) .</brief_summary>
	<brief_title>Methylprednisolone During Switch Between Natalizumab Fingolimod</brief_title>
	<detailed_description>Patients MS receive NTZ least 18 month without disease activity previous year eligible . Included patient receive either methylprednisolone ( 1 gramme , 1 day every 4 week total 3 gramme ) undistinguishable capsule placebo . Every patient initiate treatment FTY 7 week last NTZ perfusion . Methylprednisolone placebo take 4 , 8 12 week ( W4 , W8 W12 ) NTZ discontinuation . A spinal brain MRI perform baseline ( last NTZ perfusion , note W0 ) 16 18 week . The last clinical follow-up make 24 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>RelapsingRemitting Multiple Sclerosis ( Mc Donald 's 2010 criterion ) EDSS &lt; 6.0 At least18 natalizumab infusion Planned switch natalizumab fingolimod Aged 18 65 Patients must receive high dose IV methylprednisolone 5 previous year Progressive MS Uncontrolled MS natalizumab ( existence relapse previous 12 month existence gadolinium enhance lesion MRI perform last 12 month ) SEP de forme progressive Contraindication use high dose oral methylprednisolone Marked cognitive impairment alter protocole understanding Switch natalizumab disease modify treatment different fingolimod Contraindication fingolimod use Existence disease condition could alter study completion Chronic treatment steroid Acute treatment steroid ( 300mg month prior inclusion ) Contraindication gadolinium contain product injection Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Natalizumab</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Methylprednisolone</keyword>
</DOC>